Key Takeaways:
- Teva sees a promising future with FDA's acceptance of AJOVY® for pediatric migraine prevention.
- Current analyst forecasts suggest significant upside potential for Teva's stock.
- GuruFocus' GF Value estimate presents a more cautious outlook.
Teva Pharmaceutical Industries, Ltd. (NYSE: TEVA) has recently made headlines with the U.S. FDA's acceptance of its supplemental Biologics License Application for AJOVY®, a breakthrough in migraine prevention for pediatric patients. While Teva's stock has experienced an 11% dip in recent times, the company's valuation continues to sit below the analyst consensus target of $22.88. Analysts remain optimistic about Teva's trajectory, projecting a return to profitability within the next three years.
Analysts' Insights on Teva's Stock Performance
According to projections from six seasoned analysts, the average one-year price target for Teva Pharmaceutical Industries Ltd (TEVA, Financial) stands at $23.18, with estimates ranging from a high of $30.00 to a low of $18.07. This average target indicates a potential upside of 80.80% from the current market price of $12.82. Investors can explore more detailed estimates on the Teva Pharmaceutical Industries Ltd (TEVA) Forecast page.
With 11 brokerage firms contributing to the consensus recommendation, Teva's stock is currently rated at 2.1, signaling an "Outperform" status. This rating is part of a scale where 1 denotes a Strong Buy and 5 indicates a Sell.
Evaluating Teva's Fair Value with GuruFocus Metrics
In a more cautious estimate, GuruFocus posits a GF Value for Teva Pharmaceutical Industries Ltd (TEVA, Financial) of $10.79 in a year's time. This suggests a potential downside of 15.83% from the current trading price of $12.82. The GF Value is GuruFocus' calculation of the fair market value, derived from historical trading multiples, past business growth, and future business performance forecasts. Detailed data supporting this valuation is available on the Teva Pharmaceutical Industries Ltd (TEVA) Summary page.
